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Abstract Intracerebral haemorrhage (ICH) is a devastating
form of stroke that accounts for roughly 10% of all strokes
and the effects on those that survive are often debilitating. To
date, no suitable therapy exists. Recent work has examined
alterations in gene and protein expression after ICH. The focus
of this review is to outline the current knowledge of changes
in genetic and protein expression after ICH and how those
changes may affect the course of brain injury. Both animal and
human data are reviewed.
Introduction
Spontaneous intracerebral haemorrhage (ICH) is a devastating
form of stroke that results in roughly 30–50% mortality. Those
that survive often suffer debilitating permanent neurological
deficits. Currently, no satisfactory treatment exists (1, 2).
A major clinical trial failed to show a benefit for surgical
haematoma evacuation, although it is possible that a subset of
patients may benefit (3). Similarly, although initially promis-
ing (Phase II clinical trial), the use of recombinant activated
factor VII (rFVIIa) to prevent haematoma expansion failed to
produce long-term benefits (Phase III clinical trial) (4, 5).
Thus, there is a continual search for effective therapeutics.
The mechanisms of injury in ICH are becoming better
understood and have been recently reviewed (2). While much
of the neurological effects of ICH can be likely attributed to the
initial mass effect of blood in the brain, several pathogenic
events occur after the initial haemorrhage including haema-
toma expansion, midline shift, oedema formation, and blood–
brain barrier disruption. Much of the injury that occurs after
an ICH appears to be due to clot-derived factors and, therefore,
the mechanisms of injury differ from cerebral ischaemia.
Identifying changes in genomic regulation and protein expres-
sion after ICH may provide additional details of the patholo-
gical processes that occur in ICH and aid in the development of
new and more effective therapeutics. Indeed, with the advent
of microarray technology, identifying genetic changes has
become more practical. Recent studies have identified numer-
ous genes that undergo altered regulation after experimental
ICH, although it is still much less studied than cerebral
ischaemia. Here, the current knowledge of changes in genetic
expression and protein alterations that result from clinical and
experimental ICH is reviewed. Additionally, the role these
discoveries may have in the development of new therapeutics is
also discussed.
Genetic expression and protein changes in
animal models of ICH
The use of DNA micro-array technology has allowed for the
expression of thousands of genes to be tested under experi-
mental conditions for each sample. This technology has
recently been applied to a prominent experimental ICH model.
Lu et al. (6) provided strong evidence that widespread changes
in genetic expression are evident after infusion of autologous
blood into the rat striatum. Therefore, important regulatory
events likely take place in the region of the haematoma,
surrounding tissue, and overlying cortex. They found 369
genes were to be regulated by ICH, either in the striatum or in
the surrounding cortex (6). The findings in this report prompt
the need for further understanding of alterations in genomic
expression after ICH. Indeed, only 59 (16%) of the 369
regulated transcripts had been previously reported in ICH
studies (Fig. 1a). Many of the regulated genes in the stress
response, enzymes/inhibitors, and extracellular matrix cate-
gories were somewhat expected and have been reported before.
However, many categories of genes were reported for the first
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time and contain a significant percentage of total regulated
genes (Fig. 1b). Additionally, in many of the categories more
than one-third of the regulated genes underwent a greater than
fivefold regulation (Fig. 1c). In Lu et al. (6), the authors place
the genes in functional categories. While genes often fall into
multiple categories, it is important to categorize genes into
functional categories to understand the broad regulatory
changes that occur as a result of ICH. Here, it is useful to
discuss what is currently known about changes in expression in
genetic functional categories from both this report and pre-
vious work. The goal of this review is not to discuss every
reported change to mRNA or protein levels that have been
reported in experimental or clinical ICH, but, rather to high-
light important changes in expression that are likely to have
functional effects. To that end, those expression changes that
have been corroborated by observed changes in protein levels
are given the greatest consideration.
Stress and immune response
This category of genes is the best studied in terms of altered
expression after ICH. Perhaps the most prominent of stress
proteins studied in ICH are the heat shock proteins (HSPs).
These proteins in general are wide ranging in their expression
profile, with some being constitutively expressed and others,
which are inducible, are expressed at low levels under normal
conditions. Induction of HSPs occurs under a wide variety of
biological conditions and in considering the effects of induc-
tion in ICH, it is important to explore the time-course, cell
type, and spectrum of HSPs present. Several of the HSPs have
indeed been found to be up-regulated in response to experi-
mental ICH.
HSP70 induction in the brain occurs after a wide variety of
insults and serves as an indicator of cell injury (7–10). HSP70
mRNA is increased (B3-fold) after the infusion of lysed
autologous blood 24 h after the lesion (6). Additionally,
HSP70 tissue protein levels are increased in both neurons
and glia in that model, as observed by immunohistochemistry
(11). Lysed blood was required, as whole blood did not exert
this effect. Neurons, both adjacent to and spatially remote to
the haematoma, exhibited an induction of HSP70. Indeed,
HSP70 induction under these circumstances is unsurprising,
as it is induced under a wide variety of cellular insults. In
humans, plasma levels of HSP70 have been correlated with
mortality (12). HSPs are often thought to be a protective
response to stress. Thus, the induction of HSP70 before ICH
has been found to be protective in a collegenase model of ICH
(13).
The inducible haeme oxygenase-1 (HO-1), also referred to
as HSP32, converts haeme to biliverdin, carbon monoxide, and
iron. HSP32 protein has been found to be upregulated in a rat
model ICH in neurons (lysed blood only) and glia (both whole
and lysed blood) (11) through immunohistochemistry. The
induction of HSP32 protein is also detectable in striatal tissue
after experimental ICH by Western blotting (14, 15). In aged
rats, which exhibit increased brain oedema and neurological
deficits following experimental ICH (autologous blood infu-
sion), enhanced HSP32 induction relative to young rats has
been observed (14). Additionally, HSP32 is detectable in white
matter of the pig after the infusion of either whole or lysed
blood (16).
Increases in HSP32 may serve to increase the metabolism of
haeme introduced from lysed blood cells. HSP32 is involved in
the clearance of haeme from the brain and, thus, plays a role in
haematoma resolution. However, because of the potential for
haeme degradation products (e.g. iron) to be neurotoxic,
HSP32 activity may induce brain injury. In a pig model of
ICH, inhibition of HSP32 activity reduces the haematoma size
and oedema volume (17). In the rat, inhibition of HSP32 is
protective against haemoglobin-induced brain oedema (18).
The effect of HSP32 on ICH-induced brain injury likely
depends on the degree of induction and its timing. Induction
before the haemorrhage is associated with protection against
Fig. 1 Trends in genomic regulation after intracerebral haemorrhage (ICH)
[summarized from a report by Lu et al. (6)]. (a) Percentage of previously
unreported genes regulated after ICH by functional category. (b) Percen-
tage genes within each functional category relative to the total number of
genes regulated by ICH. (c) Percentage of genes within each category to
undergo more than fivefold regulation.
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oedema formation and neurological deficits resultant from
high-dose thrombin or ICH (19–21).
HSP27 is also induced in ICH with tissue mRNA increasing
in both the ipsilateral striatum (B6-fold) and the overlying
cortex (B13-fold) (6). Additionally, HSP27 protein levels are
also increased in ICH in both aged and young rats. As with
HSP32, induction of HSP27 is increased in aged rats in
association with increased neurological deficits and perihae-
matomal brain swelling (14). However, upregulation of HSP27
protein before administration of high-dose thrombin (5 U)
was found to be protective against brain oedema formation
(21). Therefore, the effects of HSP induction vary depending
on the experimental conditions, particularly the time of
induction.
The leakage of blood into the parenchyma elicits an immune
response. Part of this response includes the release of cytokines.
Indeed numerous genes that are targets of NF-kB activation
are increased in ICH (6). The immune response, including an
influx of neutrophils and monocytes into the haemorrhage, is a
part of the mechanism involved in clot resolution. Indeed,
augmentation of microglial-mediated phagocytosis is protec-
tive (22). However, as with HSP32, the immune response
may also participate in brain injury. Previous reports have
indicated that immune system inhibition in experimental ICH
is protective (23, 24).
Oxidative stress and oxidative damage occurs in experi-
mental ICH (25, 26). Indeed both mRNA and protein levels of
enzymes involved in oxidative stress are increased. Expression
of the metal-binding proteins, metallothionein-1, -2 mRNA
is increased after ICH (6). NADPH oxidase, a superoxide-
producing enzyme, also undergoes increased expression and
knockouts are less susceptible to the deleterious effects of
ICH (6, 27).
Enzymes and metabolism
After ICH, mRNA of many matrix metalloproteinase (MMP)-
related genes are up-regulated (6). Induction of these zinc-
dependent endopeptidases is thought to contribute to oedema
formation as they degrade the extracellular matrix affecting
blood–brain barrier function. In a mouse model of ICH,
MMP-9 protein was found to be colocalized with astrocytes
surrounding the haematoma region and oedema was reduced
in MMP-9 knockouts (28). Interestingly an inhibitor of MMP,
tissue inhibitor of metalloproteinase-1 (TIMP-1) also under-
goes induction (6), perhaps as a form of compensation. Indeed
in clinical ICH baseline serum MMP-9 activity is correlated
with perihaematomal volume, while TIMP levels are negatively
correlated (29–31). Additionally, increases of both MMPs and
their inhibitors tend to occur in the acute phase of injury (30).
The authors also found MMP-3 levels to be a predictor of
death. The regulation of TIMPs in ICH is also interesting. In
humans, TIMP-1 levels increase rapidly, while TIMP-2 levels
are decreased compared to controls (30). Indeed, TIMP-2 may
provide protection against blood-brain-barrier disruption
(32). In a collegenase model of ICH, mRNA from several
MMPs is increased, with the macrophage metalloelastase,
MMP-12, being most prominently regulated (B80-fold) (33).
Several enzymes related to glycolysis undergo regulation
following experimental ICH, as evidenced by changes in
mRNA (6). The authors report decreases in mRNA expression
of rate-limiting enzymes in the haematoma region (phospho-
fructokinase-M), but increases (type II hexokinase) in the
overlying cortex. This corresponds to previously observed
decreases in 2-deoxyglucose uptake in the haematoma region,
in conjunction with increased uptake in the perihaematomal
region (34).
Neurotransmitters and synaptic transmission
The effects of ICH on neurotransmitter systems have received
little attention. Interestingly, Lu et al. (6) found that in the rat
striatal blood injection model, genes associated with multiple
neurotransmitters systems were down regulated. Prominent
examples included a 15-fold down regulation in an AMPA
receptor subunit (Glu-R-C) in the striatum, a 25-fold decrease
in dopamine receptor 2 in the cortex, and a 25-fold decrease in
the muscarinic cholinergic receptor 1 in the striatum. Neuro-
chemical alterations in this model have also been observed.
Ipsilateral and contralateral dopamine levels have been found
to be increased in experimental ICH as compared with modest
increases in GABA, which may elicit the decrease in receptor
expression (35). These changes in glutamate, GABA, and
monoamine systems are an exciting finding and may be
amenable to therapeutic interventions but much work will
be needed to characterize the neuro chemical phenotype that
occurs in ICH.
Ion channels and transporters
In their genomic analysis of rat ICH, Lu et al. (6) reported a
number of changes in ion channel expression. Here, 90% of the
genes found to be regulated were previously unreported
(Fig. 1a). Most of these genes were down regulated and related
to voltage-gated potassium channels. Kcnab2, a gene asso-
ciated with the voltage-gated potassium channel beta subunit,
was found to be down regulated in both micro-array and real-
time quantitative reverse transcriptase polymerase chain reac-
tion (RT-PCR) analysis. Additionally, some other sodium and
chloride channels were also down regulated. For these newly
reported changes in ion channel mRNA, the functional
importance still needs to be determined and Western blotting
and immunohistochemistry will be needed to assess the actual
impact of these changes. However, ion channel blockers could
potentially be employed in an experimental protective ap-
proach, when changes are more fully characterized.
Iron-transport-related proteins have been extensively stu-
died in ICH and the role of iron and iron-transport proteins in
ICH has been previously reviewed (36, 37). The breakdown of
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haeme releases iron, which results in the iron accumulation in
the brain. Iron chelation can reduce ICH-induced brain injury
in animal models of ICH (38), suggesting that changes in
endogenous iron-handling proteins may also affect brain
damage. ICH is associated with increases in the iron transport
protein transferrin (Tf) and its receptor (TfR), and there are
marked increases in ferritin, a naturally occurring iron chelator
(15). Increased Tf and TfR before ICH are associated with
protection (21).
Additional categories
The genomics study by Lu et al. (6) identifies numerous
changes in mRNA of additional functional categories after
ICH. Changes in signaling proteins, for example, affect a range
of processes from growth to inflammation. Again, most of
these changes have not been previously reported and will
require much further work to assess their involvement in the
pathogenesis of ICH (39).
Needs for future research
The regulated genes discussed here present several potential
opportunities for therapeutic intervention. For example, re-
ceptor agonists or reuptake inhibitors for affected neurotrans-
mitter systems could be tested for impact on behavioral deficits
after ICH. Additionally, over-expression of outward-conduct-
ing potassium channels has been found to be neuroprotective
against excitotoxic lesions (40). Here, it may be that the down
regulation of potassium channels contributes to excitoxicity.
The study by Lu et al. (6) provides an important step in
understanding genomic changes after ICH. Ultimately, new
therapeutic pathways may be discovered as a result of these
findings. However, much intermediate research will first need
to be conducted:
(1) Validation of the micro-array findings of relevant genes
will need to be performed.
(2) Analysis of protein levels or conformation changes would
provide additional convincing support. It is widely known that
changes in genetic expression do not always translate to
changes in protein expression. Therefore, to understand the
functional changes that occur after ICH it is important to
identify changes in protein levels. Here, we have attempted to
integrate current knowledge of mRNA and protein changes but
much work is still required to determine the extent to which
changes in gene expression are reflected in actual changes in
protein levels or activity.
(3) The cell types (e.g. neurons, glia, endothelial cells) in-
volved will also give important information on the potential
role of these changes. Laser microdissection would allow such
an examination.
(4) There is also much work to be done examining the
temporal patterns of gene and protein expression. The geno-
mic study of Lu et al. (6) looked at a single time point (24 h)
after ICH. However, much of the injury that occurs early after
an ICH and whether changes in endogenous protein levels
affect that injury are still uncertain. Similarly, there may be late
changes that affect neuronal plasticity, neurogenesis, and
behavioral recovery after an ICH.
(5) Mechanistic research on the implications of altered gene/
protein regulation is necessary to identify the role of these
changes in pathogenesis and/or the potential for therapeutic
modulation. It is often unclear whether some of the changes in
gene/protein expression that occur after ICH are beneficial or
detrimental. This is exemplified by up-regulation in HSP32
and inflammatory mediators which may be necessary for clot
resolution but may also enhance brain injury. Indeed, the
effects of such up-regulation may depend on the nature (size/
site) of the initial haemorrhage. Thus, inhibitor studies and/or
gene knockdown experiments are needed to help define the
role of changes in gene/protein regulation.
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